BioCatalyst

TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab — catalyst calendar

1 verified catalyst event(s) referencing TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab, each linked to its official source. Verified as of 2026-10-03.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-02-01
in 4mo
ESTIMATED
 READOUT
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locall
Phase 1/2 · Hepatocellular Carcinoma
 Tvardi Therapeutics, Incorporated TTI-101, Pembrolizumab, Atezolizumab, Be ClinicalTrials.gov ↗
✓ Source-checked 2026-10-03
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.